Translational Development of Microbiome‐Based Therapeutics: Kinetics of E. coli Nissle and Engineered Strains in Humans and Nonhuman Primates

Understanding the pharmacology of microbiome‐based therapeutics is required to support the development of new medicines. Strains of E. coli Nissle (EcN) were genetically modified and administered to cynomolgus monkeys at doses of 1 × 109 and 1 × 1012 colony‐forming units (CFU)/day for 28 days. A clinical study to evaluate the exposure and clearance of EcN in healthy volunteers was also performed. Healthy subjects received oral doses of EcN, 2.5 to 25 × 109 CFU 3 times daily for 28 days or a single day. In cynomolgus monkeys, replicating strains yielded higher fecal concentrations than nonreplicating strains and persisted for longer following cessation of dosing. In the clinical study, all subjects cleared EcN following cessation of dosing with median clearance of 1 week. Quantitative methodology can be applied to microbiome‐based therapeutics, and similar kinetics and clearance were observed for EcN in cynomolgus monkeys and humans.

[1]  S. Perna,et al.  Using probiotics in clinical practice: Where are we now? A review of existing meta-analyses , 2017, Gut microbes.

[2]  T. Wassenaar Insights from 100 Years of Research with Probiotic E. Coli , 2016, European journal of microbiology & immunology.

[3]  J. Gabry,et al.  Bayesian Applied Regression Modeling via Stan , 2016 .

[4]  R. Knight,et al.  Variable responses of human and non-human primate gut microbiomes to a Western diet , 2015, Microbiome.

[5]  M. Gorzelak,et al.  Methods for Improving Human Gut Microbiome Data by Reducing Variability through Sample Processing and Storage of Stool , 2015, PloS one.

[6]  B. Jefferson,et al.  The Characterization of Feces and Urine: A Review of the Literature to Inform Advanced Treatment Technology , 2015, Critical reviews in environmental science and technology.

[7]  T. Dandekar,et al.  Complete genome sequence of the gram-negative probiotic Escherichia coli strain Nissle 1917. , 2014, Journal of biotechnology.

[8]  K. Zimmermann,et al.  Voluntarily exposure to a single, high dose of probiotic Escherichia coli results in prolonged colonisation. , 2014, Beneficial microbes.

[9]  B. White,et al.  Fecal microbiomes of non‐human primates in Western Uganda reveal species‐specific communities largely resistant to habitat perturbation , 2014, American journal of primatology.

[10]  R. Linhardt,et al.  Draft Genome Sequence of Escherichia coli Strain Nissle 1917 (Serovar O6:K5:H1) , 2013, Genome Announcements.

[11]  Paul Morgan,et al.  Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. , 2012, Drug discovery today.

[12]  W. Kruis,et al.  Survival of the probiotic Escherichia coli Nissle 1917 (EcN) in the gastrointestinal tract given in combination with oral mesalamine to healthy volunteers , 2010, Inflammatory bowel diseases.

[13]  H. Krammer,et al.  Probiotische Arzneimitteltherapie mit E. coli Stamm Nissle 1917 (EcN): Ergebnisse einer prospektiven Datenerhebung mit 3807 Patienten , 2006 .

[14]  P. Dítě,et al.  [Effect of administration of Escherichia coli Nissle (Mutaflor) on intestinal colonisation, endo-toxemia, liver function and minimal hepatic encephalopathy in patients with liver cirrhosis]. , 2006, Vnitrni lekarstvi.

[15]  B. Cukrowska,et al.  Specific Proliferative and Antibody Responses of Premature Infants to Intestinal Colonization with Nonpathogenic Probiotic E. coli Strain Nissle 1917 , 2002, Scandinavian journal of immunology.

[16]  P. Brigidi,et al.  Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis , 1999, Alimentary pharmacology & therapeutics.

[17]  J. Mordenti,et al.  Man versus beast: pharmacokinetic scaling in mammals. , 1986, Journal of pharmaceutical sciences.

[18]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[19]  John M. DeSesso,et al.  Contrasting the Gastrointestinal Tracts of Mammals: Factors that Influence Absorption , 2008 .

[20]  G. Feierl,et al.  Are probiotics detectable in human feces after oral uptake by healthy volunteers? , 2007, Wiener klinische Wochenschrift.

[21]  T. Haahtela,et al.  Probiotics and prebiotic galacto-oligosaccharides in the prevention of allergic diseases: a randomized, double-blind, placebo-controlled trial. , 2007, The Journal of allergy and clinical immunology.

[22]  R. von Bünau,et al.  [Probiotic drug therapy with E. coli strain Nissle 1917 (EcN): results of a prospective study of the records of 3,807 patients]. , 2006, Zeitschrift fur Gastroenterologie.